Curative surgical resection of adrenocortical carcinoma: Determining long-term outcome based on conditional disease-free probability

Annals of Surgery

Volumn 265, Issue 1, 2017, Pages 197-204

  Kim, Yuhree ^a   Margonis, Georgios A ^a   Prescott, Jason D ^a   Tran, Thuy B ^b   Postlewait, Lauren M ^c   Maithel, Shishir K ^c   Wang, Tracy S ^d   Glenn, Jason A ^d   Hatzaras, Ioannis ^e   Shenoy, Rivfka ^e   Phay, John E ^f   Keplinger, Kara ^f   Fields, Ryan C ^g   Jin, Linda X ^g   Weber, Sharon M ^h   Salem, Ahmed ^h   Sicklick, Jason K ⁱ   Gad, Shady ⁱ   Yopp, Adam C ^j   Mansour, John C ^j   Duh, Quan Yang ^k   Seiser, Natalie ^k   Solorzano, Carmen C ^l   Kiernan, Colleen M ^l   Votanopoulos, Konstantinos I ^m   Levine, Edward A ^m   Poultsides, George A ^b   Pawlik, Timothy M ^a   more..

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MEDICAL COLLEGE OF WISCONSIN   (United States)

^e NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f OHIO STATE UNIVERSITY   (United States)

^g WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

ⁱ UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^j UNIVERSITY OF TEXAS AT DALLAS   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

^l VANDERBILT UNIVERSITY   (United States)

^m WAKE FOREST SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Adrenocortical carcinoma; Conditional probability; Outcomes; Surgery

Indexed keywords

ANDROGEN; ANTINEOPLASTIC AGENT; ESTROGEN; GLUCOCORTICOID; MINERALOCORTICOID; MITOTANE;

ADJUVANT CHEMOTHERAPY; ADRENAL CORTEX CARCINOMA; ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MITOSIS INDEX; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; ADOLESCENT; ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; FACTUAL DATABASE; MIDDLE AGED; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; ADULT; AGED; AGED, 80 AND OVER; DATABASES, FACTUAL; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84952685596     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0000000000001527     Document Type: Article

References (42)

1. Fassnacht M, Johanssen S, Quinkler M, et al. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: Proposal for a Revised TNM Classification. Cancer. 2009; 115: 243-250.
2. Schteingart DE, Doherty GM, Gauger PG, et al. Management of patients with adrenal cancer: Recommendations of an international consensus conference. Endocr Relat Cancer. 2005; 12: 667-680.
3. Sun M, Abdollah F, Bianchi M, et al. Conditional survival of patients with urothelial carcinoma of the urinary bladder treated with radical cystectomy. Eur J Cancer. 2012; 48: 1503-1511.
4. Bilimoria KY, Shen WT, Elaraj D, et al. Adrenocortical carcinoma in the United States: Treatment utilization and prognostic factors. Cancer. 2008; 113: 3130-3136.
5. Terzolo M, Baudin AE, Ardito A, et al. Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection. Eur J Endocrinol. 2013; 169: 263-270.
6. Gratian L, Pura J, Dinan M, et al. Treatment patterns and outcomes for patients with adrenocortical carcinoma associated with hospital case volume in the United States. Ann Surg Oncol. 2014; 21: 3509-3514.
7. Terzolo M, Angeli A, Fassnacht M, et al. Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med. 2007; 356: 2372-2380.
8. Icard P, Goudet P, Charpenay C, et al. Adrenocortical carcinomas: Surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group. World J Surg. 2001; 25: 891-897.
9. Sidhu S, Sywak M, Robinson B, et al. Adrenocortical cancer: Recent clinical and molecular advances. Curr Opin Oncol. 2004; 16: 13-18.
10. Fassnacht M, Libe R, Kroiss M, et al. Adrenocortical carcinoma: A clinician's update. Nat Rev Endocrinol. 2011; 7: 323-335.
11. Kebebew E, Reiff E, Duh QY, et al. Extent of disease at presentation and outcome for adrenocortical carcinoma: Have we made progress? World J Surg. 2006; 30: 872-878.
12. Asare EA, Wang TS, Winchester DP, et al. A novel staging system for adrenocortical carcinoma better predicts survival in patients with stage I/II disease. Surgery. 2014; 156: 1378-1385.
13. Lughezzani G, SunM, Perrotte P, et al. The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the international union against cancer-staging system: A North American validation. Eur J Cancer. 2010; 46: 713-719.
14. Mertens AC, Yong J, Dietz AC, et al. Conditional survival in pediatric malignancies: Analysis of data from the Childhood Cancer Survivor Study and the Surveillance, Epidemiology, and End Results Program. Cancer. 2015; 121: 1108-1117.
15. Nathan H, de Jong MC, Pulitano C, et al. Conditional survival after surgical resection of colorectal liver metastasis: An international multiinstitutional analysis of 949 patients. J Am Coll Surg. 2010; 210: 755-764; 764-766.
16. Henson DE, Ries LA, Carriaga MT. Conditional survival of 56,268 patients with breast cancer. Cancer. 1995; 76: 237-242.
17. Skuladottir H, Olsen JH. Conditional survival of patients with the four major histologic subgroups of lung cancer in Denmark. J Clin Oncol. 2003; 21: 3035-3040.
18. Wang SJ, Emery R, Fuller CD, et al. Conditional survival in gastric cancer: A SEER database analysis. Gastric Cancer. 2007; 10: 153-158.
19. Mayo SC, Nathan H, Cameron JL, et al. Conditional survival in patients with pancreatic ductal adenocarcinoma resected with curative intent. Cancer. 2012; 118: 2674-2681.
20. Cucchetti A, Piscaglia F, Cescon M, et al. Conditional survival after hepatic resection for hepatocellular carcinoma in cirrhotic patients. Clin Cancer Res. 2012; 18: 4397-4405.
21. Ploussard G, Shariat SF, Dragomir A, et al. Conditional survival after radical cystectomy for bladder cancer: Evidence for a patient changing risk profile over time. Eur Urol. 2014; 66: 361-370.
22. Kurta ML, Edwards RP, Moysich KB, et al. Prognosis and conditional disease-free survival among patients with ovarian cancer. J Clin Oncol. 2014; 32: 4102-4112.
23. Banerjee M, Muenz DG, Worden FP, et al. Conditional survival in patients with thyroid cancer. Thyroid. 2014; 24: 1784-1789.
24. Facciorusso A, Del Prete V, Antonino M, et al. Conditional survival analysis of hepatocellular carcinoma patients treated with radiofrequency ablation. Hepatol Res. 2015; 45: E62-E72.
25. Polley MY, Lamborn KR, Chang SM, et al. Conditional probability of survival in patients with newly diagnosed glioblastoma. J Clin Oncol. 2011; 29: 4175-4180.
26. Erickson LA, Rivera M, Zhang J. Adrenocortical carcinoma: Review and update. Adv Anat Pathol. 2014; 21: 151-159.
27. Bischof DA, Kim Y, Dodson R, et al. Conditional disease-free survival after surgical resection of gastrointestinal stromal tumors: A multi-institutional analysis of 502 patients. JAMA Surg. 2015; 150: 299-306.
28. Burnand B, Kernan WN, Feinstein AR. Indexes and boundaries for "quantitative significance" in statistical decisions. J Clin Epidemiol. 1990; 43: 1273-1284.
29. Carnaille B. Adrenocortical carcinoma: Which surgical approach? Langenbecks Arch Surg. 2012; 397: 195-199.
30. Dikken JL, Baser RE, Gonen M, et al. Conditional probability of survival nomogram for 1-, 2-, and 3-year survivors after an R0 resection for gastric cancer. Ann Surg Oncol. 2013; 20: 1623-1630.
31. Harrison LE, Gaudin PB, Brennan MF. Pathologic features of prognostic significance for adrenocortical carcinoma after curative resection. Arch Surg. 1999; 134: 181-185.
32. Abiven G, Coste J, Groussin L, et al. Clinical and biological features in the prognosis of adrenocortical cancer: Poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. J Clin Endocrinol Metab. 2006; 91: 2650-2655.
33. Berruti A, Terzolo M, Sperone P, et al. Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: A large prospective phase II trial. Endocr Relat Cancer. 2005; 12: 657-666.
34. Ribeiro RC, Michalkiewicz EL, Figueiredo BC, et al. Adrenocortical tumors in children. Braz J Med Biol Res. 2000; 33: 1225-1234.
35. Icard P, Louvel A, Chapuis Y. Survival rates and prognostic factors in adrenocortical carcinoma. World J Surg. 1992; 16: 753-758.
36. Kendrick ML, Lloyd R, Erickson L, et al. Adrenocortical carcinoma: Surgical progress or status quo? Arch Surg. 2001; 136: 543-549.
37. Stojadinovic A, Ghossein RA, Hoos A, et al. Adrenocortical carcinoma: Clinical, morphologic, and molecular characterization. J Clin Oncol. 2002; 20: 941-950.
38. Canter DJ,Mallin K, Uzzo RG, et al. Association of tumor size with metastatic potential and survival in patients with adrenocortical carcinoma: An analysis of the National Cancer Database. Can J Urol. 2013; 20: 6915-6921.
39. Luton JP, Cerdas S, Billaud L, et al. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med. 1990; 322: 1195-1201.
40. Vassilopoulou-Sellin R, Schultz PN. Adrenocortical carcinoma. Clinical outcome at the end of the 20th century. Cancer. 2001; 92: 1113-1121.
41. Zini L, Capitanio U, Jeldres C, et al. External validation of a nomogram predicting mortality in patients with adrenocortical carcinoma. BJU Int. 2009; 104: 1661-1667.
42. Ploussard G, Xylinas E, Lotan Y, et al. Conditional survival after radical nephroureterectomy for upper tract carcinoma. Eur Urol. 2015; 67: 803-812.